World's Best Scientists 2026 revealed!
Lewis B. Silverman

Lewis B. Silverman

D-Index & Metrics

Medicine

D-Index
94
Citations
36511
World Ranking
10400
National Ranking
5355

Lewis B. Silverman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Lewis B. Silverman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 361 publications — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Lewis B. Silverman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Lewis B. Silverman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Lewis B. Silverman is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with a particular focus on acute lymphoblastic leukemia and related pediatric health issues. Their research output encompasses a wide range of topics within medicine, reflecting a strong interdisciplinary approach centered on oncology and child health.

The scientist's research spans several interconnected fields of study including public health, environmental and occupational health, pediatrics, perinatology and child health, hematology, oncology, and speech and hearing. This multidisciplinary engagement highlights their broad interest in both the biological and clinical aspects of disease as well as patient quality of life.

Lewis B. Silverman's scholarly work largely concentrates on the following main topics:

  • Acute Lymphoblastic Leukemia research
  • Childhood Cancer Survivors' Quality of Life
  • Adolescent and Pediatric Healthcare
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research

Recent papers authored or co-authored by Silverman demonstrate a focus on clinical guidelines, treatment outcomes, and molecular characterizations of leukemia. These include:

  • Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study, 2020, Journal of Clinical Oncology
  • Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL, 2020, Blood
  • Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001, 2021, Blood Advances
  • Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001, 2021, Journal of Clinical Oncology

Collaborations form an important part of Silverman's research activities, with frequent co-authors including Peter D. Cole, Kara M. Kelly, Jennifer J.G. Welch, Andrew E. Place, and Kristen E. Stevenson. The repeated collaboration with these researchers suggests a networked approach to clinical and translational oncology research.

Silverman's work has been published predominantly in specialized venues that address hematology, oncology, and pediatric cancer research. The primary publication venues include:

  • Blood
  • Pediatric Blood & Cancer
  • Journal of Clinical Oncology
  • Blood Advances
  • Cancer Epidemiology Biomarkers & Prevention

The body of work attributed to Lewis B. Silverman encompasses more than two hundred publications, affirming a focused research career in medicine with an emphasis on the clinical, molecular, and quality-of-life dimensions of leukemia and pediatric oncology.

Best Publications

  • Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

    Andrew P. Weng;Andrew P. Weng;Adolfo A. Ferrando;Adolfo A. Ferrando;Woojoong Lee;Woojoong Lee;John P. Morris;John P. Morris

  • Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia

    Todd R. Golub;Scott A. Armstrong;Stanley J. Korsmeyer

  • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

    Lewis B. Silverman;Richard D. Gelber;Virginia Kimball Dalton;Barbara L. Asselin

  • Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

    Ching Hon Pui;Jun J. Yang;Stephen P. Hunger;Rob Pieters

  • An Oncogenic Super-Enhancer Formed Through Somatic Mutation of a Noncoding Intergenic Element

    Marc R. Mansour;Marc R. Mansour;Brian J. Abraham;Lars Anders;Alla Berezovskaya

  • Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia

    M Arico;MG Valsecchi;B Camitta;M Schrappe

  • A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

    Rob Pieters;Martin Schrappe;Paola De Lorenzo;Ian Hann

  • The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia

    Steven E. Lipshultz;Nader Rifai;Virginia M. Dalton;Donna E. Levy

  • L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

    Rob Pieters;Stephen P. Hunger;Joachim Boos;Carmelo Rizzari

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias

    Andrei V. Krivtsov;Zhaohui Feng;Madeleine E. Lemieux;Joerg Faber

  • Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

    Albert Moghrabi;Donna E. Levy;Barbara L. Asselin;Ronald Barr

  • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

    Steven E Lipshultz;Rebecca E Scully;Stuart R Lipsitz;Stephen E Sallan;Stephen E Sallan

  • Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification

    Scott A Armstrong;Andrew L Kung;Andrew L Kung;Meghann E Mabon;Lewis B Silverman;Lewis B Silverman

  • Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

    Ching-Hon Pui;Paul S Gaynon;James M Boyett;Judith M Chessells

  • High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

    Alejandro Gutierrez;Alejandro Gutierrez;Takaomi Sanda;Ruta Grebliunaite;Arkaitz Carracedo

  • Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation

    Adolfo A. Ferrando;Scott A. Armstrong;Donna S. Neuberg;Stephen E. Sallan

  • Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience

    John M. Goldberg;Lewis B. Silverman;Donna E. Levy;Virginia Kimball Dalton

  • Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

    Lynda M. Vrooman;Kristen E. Stevenson;Jeffrey G. Supko;Jane O'Brien

  • Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985―2000)

    Lewis B. Silverman;Kristen E. Stevenson;Jane E. O’Brien;Barbara L. Asselin

Frequent Co-Authors

Stephen E. Sallan
Stephen E. Sallan Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Stephen P. Hunger
Stephen P. Hunger University of Pennsylvania
Mignon L. Loh
Mignon L. Loh University of California, San Francisco
Steven E. Lipshultz
Steven E. Lipshultz University at Buffalo, State University of New York
Daniel J. DeAngelo
Daniel J. DeAngelo Harvard University
Ching-Hon Pui
Ching-Hon Pui St. Jude Children's Research Hospital
A. Thomas Look
A. Thomas Look Harvard University
Rob Pieters
Rob Pieters Princess Máxima Center
Jeffery L. Kutok
Jeffery L. Kutok Epizyme (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online healthcare degrees is an excellent way to fast-track your career or advance your current skills. Many nursing professionals wonder, for example, does rn to bsn require clinicals? Some flexible RN to BSN programs may allow you to earn your degree entirely online, while others include clinical requirements, making it important to verify the details before enrolling.

For nurses with a master's degree, there are also options to complete a shortest post master's dnp program, accelerating your pathway to a Doctor of Nursing Practice (DNP) in as little as one year. If you are searching for the fastest route overall, some of the shortest dnp program choices focus on working professionals and emphasize practical, leadership-oriented coursework.

Entry-level options also exist. Aspiring nurses can enroll in fast track lpn programs online and quickly qualify for licensure, often in a matter of months. Online healthcare education continues to evolve, offering options for both newcomers and experienced clinicians to reach their goals efficiently.

Best Scientists Citing Lewis B. Silverman

Trending Scientists

Recently Published Articles